The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Assessment of COVID vaccine knowledge and hesitancy in an ethnic minority oncology patient population.
 
Matthew Lee
No Relationships to Disclose
 
Emily Miao
No Relationships to Disclose
 
Shankar Viswanathan
No Relationships to Disclose
 
Bruce D. Rapkin
No Relationships to Disclose
 
Balazs Halmos
Consulting or Advisory Role - Apollomics; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Foundation Medicine; Genentech/Roche; Guardant Health; Janssen Oncology; Lilly; Merck; Novartis; Pfizer; Spectrum Pharmaceuticals; Takeda; Turning Point Therapeutics; Veracyte
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen; AstraZeneca (Inst); BeiGene; Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elevation Oncology; GlaxoSmithKline (Inst); Guardant Health (Inst); Janssen Oncology (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
 
Sanjay Goel
Stock and Other Ownership Interests - Johnson and Johnson; Merck; Moderna Therapeutics
Honoraria - Amgen; Merck
Research Funding - BeiGene (Inst); Deciphera (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); PharmaMar (Inst); Takeda (Inst); TLC PharmaChem (Inst)
Patents, Royalties, Other Intellectual Property - I have a patent with a co-inventor, John Mariadason, Ph.D, entitled "Method Of Determining The Sensitivity Of Cancer Cells To EGFR Inhibitors Including Cetuximab, Panitumumab And Erlotinib.", Patent No. 20090258364